Prostate Cancer Clinical Trials in Detroit

Showing 221-240 of 408 trials

Pembro and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer

NCT03406858

This phase II trial studies how well pembrolizumab and HER2Bi-armed activated T cells work in treating patients with castration resistant prostate cancer that has spread to other places in the body. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. HER2Bi-armed activated T cells are made using T cells and may target and kill cancer cells. Giving pembrolizumab and HER2Bi-armed activated T cells may work better in treating patients with castration resistant prostate cancer.

Castration Levels of TestosteroneCastration-Resistant Prostate CarcinomaProstate Carcinoma Metastatic in the Bone+2 more

Barbara Ann Karmanos Cancer Institute15 participantsStarted Jun 2018

Detroit, Michigan, United States

COMPLETEDPhase 1< 1 mile

A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors

NCT03849469

This is a Phase 1, multiple dose, ascending-dose escalation study and expansion study designed to define a maximum tolerated dose and/or recommended dose of XmAb22841 monotherapy and in combination with pembrolizumab; to assess safety, tolerability, pharmacokinetics, immunogenicity, and anti-tumor activity of XmAb22841 monotherapy and in combination with pembrolizumab in subjects with select advanced solid tumors.

MelanomaCervical CarcinomaPancreatic Carcinoma+20 more

Xencor, Inc.78 participantsStarted May 2019

Encinitas, California, United States • La Jolla, California, United States • La Jolla, California, United States +25 more locations

Pembro and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer

A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors

Prostate Cancer Trials in Other Cities

Radiation Therapy in Treating Patients With Stage II Prostate Cancer

Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases

Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer

Hormone Therapy and Radiation Therapy or Hormone Therapy and Radiation Therapy Followed by Docetaxel and Prednisone in Treating Patients With Localized Prostate Cancer

Radiation Therapy With or Without Bicalutamide for Recurrent pT3N0 Prostate Cancer After Radical Prostatectomy

Diet in Altering Disease Progression in Patients With Prostate Cancer on Active Surveillance

Reducing the Effects of Active Surveillance Stress, Uncertainty and Rumination Thru Engagement in Mindfulness Education

Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

Ultrasound-Guided Implant Radiation Therapy in Treating Patients With Locally Recurrent Prostate Cancer Previously Treated With External-Beam Radiation Therapy

Radiation Therapy in Treating Patients With Prostate Cancer

PSMA-PET Registry for Recurrent Prostate Cancer

Evaluation of Diet and Exercise in Prostate Cancer Patients

Effect of GTx-758 on Total and Free Testosterone Levels in Men With Prostate Cancer

OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone

Identification of Genes Associated With Cancer in Patients and Siblings Who Have Cancer

PROCLAIM: Germline Genetic Testing for Prostate Cancer Patients

Pioneering Advances in Care and Education (PACE)

A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate

Other Conditions in Detroit